36.22
price down icon1.72%   -0.635
after-market After Hours: 36.41 0.19 +0.52%
loading
Exelixis Inc stock is traded at $36.22, with a volume of 4.88M. It is down -1.72% in the last 24 hours and down -17.82% over the past month. Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$36.85
Open:
$36.69
24h Volume:
4.88M
Relative Volume:
1.37
Market Cap:
$9.88B
Revenue:
$2.17B
Net Income/Loss:
$521.27M
P/E Ratio:
20.46
EPS:
1.77
Net Cash Flow:
$633.79M
1W Performance:
-19.13%
1M Performance:
-17.82%
6M Performance:
+9.26%
1Y Performance:
+54.46%
1-Day Range:
Value
$36.12
$37.67
1-Week Range:
Value
$36.12
$46.43
52-Week Range:
Value
$23.21
$49.62

Exelixis Inc Stock (EXEL) Company Profile

Name
Name
Exelixis Inc
Name
Phone
(650) 837-7000
Name
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Name
Employee
1,147
Name
Twitter
@exelixisinc
Name
Next Earnings Date
2025-07-28
Name
Latest SEC Filings
Name
EXEL's Discussions on Twitter

Compare EXEL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
EXEL
Exelixis Inc
36.22 9.92B 2.17B 521.27M 633.79M 1.77
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.87 120.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.46 59.88B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
392.24 44.31B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
670.33 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.13 32.46B 3.81B -644.79M -669.77M -6.24

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-08-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jun-24-25 Upgrade Stephens Equal-Weight → Overweight
Feb-24-25 Downgrade Wells Fargo Overweight → Equal Weight
Jan-27-25 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-24-25 Downgrade Oppenheimer Outperform → Perform
Dec-20-24 Downgrade BMO Capital Markets Outperform → Market Perform
Dec-17-24 Downgrade BofA Securities Buy → Neutral
Oct-16-24 Reiterated RBC Capital Mkts Outperform
Sep-19-24 Initiated UBS Neutral
Apr-11-24 Downgrade Barclays Overweight → Equal Weight
Dec-19-23 Initiated BTIG Research Buy
Dec-15-23 Initiated Citigroup Buy
Sep-26-23 Initiated H.C. Wainwright Buy
Aug-22-23 Reiterated Oppenheimer Outperform
Aug-08-23 Initiated SVB Securities Market Perform
Jul-11-23 Resumed Morgan Stanley Equal-Weight
May-10-23 Resumed Piper Sandler Overweight
Mar-09-23 Initiated Wells Fargo Overweight
Jan-26-23 Initiated Credit Suisse Outperform
Oct-18-22 Initiated JMP Securities Mkt Outperform
Jun-24-22 Initiated BMO Capital Markets Outperform
Nov-19-21 Initiated Piper Sandler Overweight
Nov-03-21 Resumed Jefferies Buy
Oct-07-21 Initiated Jefferies Buy
Aug-06-21 Reiterated H.C. Wainwright Buy
Jun-15-21 Initiated H.C. Wainwright Buy
May-18-21 Resumed Goldman Sell
Mar-31-21 Initiated Credit Suisse Outperform
Mar-12-21 Initiated Wolfe Research Outperform
Mar-04-20 Initiated Barclays Overweight
Jan-13-20 Initiated SunTrust Buy
Nov-13-19 Initiated BofA/Merrill Buy
Mar-18-19 Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-17-18 Initiated Goldman Neutral
Sep-10-18 Initiated Morgan Stanley Underweight
May-11-18 Reiterated Needham Buy
Oct-17-17 Reiterated Needham Buy
Oct-17-17 Reiterated RBC Capital Mkts Outperform
Oct-16-17 Reiterated SunTrust Buy
Sep-22-17 Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17 Initiated RBC Capital Mkts Outperform
Sep-12-17 Reiterated Needham Buy
Jul-14-17 Initiated SunTrust Buy
Mar-31-17 Initiated Needham Buy
Mar-16-17 Initiated Oppenheimer Perform
Feb-28-17 Downgrade Stifel Buy → Hold
Nov-03-16 Initiated Deutsche Bank Buy
Oct-10-16 Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16 Reiterated Stifel Buy
View All

Exelixis Inc Stock (EXEL) Latest News

pulisher
Jul 31, 2025

What are analysts’ price targets for Exelixis Inc. in the next 12 monthsLow Risk Strategy With Low Risk - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - PR Newswire

Jul 31, 2025
pulisher
Jul 31, 2025

Exelixis shares tumble over 12% after revenue miss and zanzalintinib trial halt - MSN

Jul 31, 2025
pulisher
Jul 31, 2025

Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards (NASDAQ:EXEL) - Seeking Alpha

Jul 31, 2025
pulisher
Jul 31, 2025

Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint - MSN

Jul 31, 2025
pulisher
Jul 31, 2025

Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT - MSN

Jul 31, 2025
pulisher
Jul 30, 2025

Is Exelixis Inc. a Top Dividend Stock to Watch in 2025Entry and Exit Strategy Optimizer Tool Tested - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance

Jul 30, 2025
pulisher
Jul 30, 2025

EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues - MSN

Jul 30, 2025
pulisher
Jul 30, 2025

Exelixis, Inc. (NASDAQ:EXEL) Q2 2025 Earnings Call Transcript - Insider Monkey

Jul 30, 2025
pulisher
Jul 29, 2025

Exelixis Inc. Forms Double Bottom Pattern — Eyes on BreakoutConservative Long Term Growth Plans Under Review - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Is Exelixis Inc. Forming a Consolidation BaseTop Performing Stock Insights Released Daily - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

U.S. Indexes Decreased Tuesday; Exelixis Posted Biggest Loss - Barron's

Jul 29, 2025
pulisher
Jul 29, 2025

Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase - MSN

Jul 29, 2025
pulisher
Jul 29, 2025

Exelixis stock price target lowered to $45 at RBC on lifecycle cuts - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

Truist Securities lowers Exelixis stock price target to $49 on mixed results - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

Exelixis stock price target raised to $41 from $38 at Stifel on NET launch - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

Exelixis Stuns Analyst With Q2 Miss, Trial Delays, Phase 3 HaltExelixis (NASDAQ:EXEL) - Benzinga

Jul 29, 2025
pulisher
Jul 29, 2025

All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy - Yahoo Finance

Jul 29, 2025
pulisher
Jul 29, 2025

Exelixis leans on zanzalintinib as cabozantinib nears patent expiry - S&P Global

Jul 29, 2025
pulisher
Jul 29, 2025

Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

Jul 29, 2025
pulisher
Jul 29, 2025

S&P 500 Futures Climb in Premarket Trading; Whirlpool, Exelixis Lag - Barron's

Jul 29, 2025
pulisher
Jul 29, 2025

Exelixis fall over 12% after revenue miss, halts zanzalintinib trial By Investing.com - Investing.com Nigeria

Jul 29, 2025
pulisher
Jul 29, 2025

UnitedHealth, Sarepta, UPS, Whirlpool, VeriSign, Cadence Design, Exelixis, and More Market Movers - Barron's

Jul 29, 2025
pulisher
Jul 29, 2025

Exelixis stock rating reiterated by JMP analyst despite sales miss - Investing.com Nigeria

Jul 29, 2025
pulisher
Jul 29, 2025

Exelixis Shares Plunge 12.14% on Revenue Miss - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Exelixis 2025 Q2 Earnings Mixed Performance as Net Income Declines 18% - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Exelixis Q2 Revenue Falls 11 Percent - AOL.com

Jul 29, 2025
pulisher
Jul 29, 2025

Exelixis Inc (EXEL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges - Yahoo Finance

Jul 29, 2025
pulisher
Jul 29, 2025

Exelixis Inc (EXEL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges By GuruFocus - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

Exelixis’s SWOT analysis: cabo success, zanza potential drive stock outlook - Investing.com

Jul 29, 2025
pulisher
Jul 29, 2025

Exelixis Reports Q2 2025 Financial Results and Updates - TipRanks

Jul 29, 2025
pulisher
Jul 28, 2025

Exelixis: Q2 Earnings Snapshot - The Washington Post

Jul 28, 2025
pulisher
Jul 28, 2025

Exelixis Beats On Earnings As Cancer Drugs Drive Growth - Finimize

Jul 28, 2025
pulisher
Jul 28, 2025

Earnings call transcript: Exelixis beats EPS forecasts in Q2 2025 By Investing.com - Investing.com Nigeria

Jul 28, 2025
pulisher
Jul 28, 2025

Earnings call transcript: Exelixis beats EPS forecasts in Q2 2025 - Investing.com

Jul 28, 2025
pulisher
Jul 28, 2025

Exelixis slides 12% on Q2 miss, pipeline update (EXEL:NASDAQ) - Seeking Alpha

Jul 28, 2025
pulisher
Jul 28, 2025

Exelixis Q2 2025 Earnings Call Transcript - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update - BioSpace

Jul 28, 2025
pulisher
Jul 28, 2025

After-hours movers: Western Union, Whirlpool, Exelixis, and more By Investing.com - Investing.com Canada

Jul 28, 2025
pulisher
Jul 28, 2025

Exelixis (EXEL) Beats Q2 Earnings Estimates - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

Exelixis Q2 Earnings: Surpassing Expectations Amid Revenue ChallengesNews and Statistics - IndexBox

Jul 28, 2025
pulisher
Jul 28, 2025

How strong is Exelixis Inc. company’s balance sheetRetirement Planning Insights For 2025 - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

EXELIXIS, INC. SEC 10-Q Report - TradingView

Jul 28, 2025
pulisher
Jul 28, 2025

Exelixis shares tumble as revenue miss and weak guidance disappoint - Investing.com Australia

Jul 28, 2025
pulisher
Jul 28, 2025

Exelixis shares tumble as revenue miss and weak guidance disappoint By Investing.com - Investing.com India

Jul 28, 2025
pulisher
Jul 28, 2025

Exelixis earnings beat by $0.11, revenue fell short of estimates - Investing.com Canada

Jul 28, 2025

Exelixis Inc Stock (EXEL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$74.89
price down icon 3.43%
$36.80
price down icon 0.86%
$107.28
price up icon 2.00%
$26.37
price down icon 1.09%
$107.50
price down icon 2.32%
biotechnology ONC
$301.13
price up icon 0.40%
Cap:     |  Volume (24h):